Biosimilars face a potential void as biologics lose exclusivity, prompting urgent calls for policy reform and enhanced ...

Number 5: Long-term data from the SAME study confirm that switching to infliximab biosimilars is safe and effective for ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more ...

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption ...

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for ...

Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more ...